Autres langues Vector Science and Therapeutics Corp.

Actions

PAIN

CA92244M1041

Sociétés holdings

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:33 05/08/2026			Varia. 5j.	Varia. 1 janv.
1,640 ^CAD	0,00 %		+7,89 %	+3 180,00 %

28/07	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC et Wynn Pharmaceuticals LLC annoncent une collaboration stratégique pour le développement et la fabrication de produits médicaux de soins critiques	CI
24/07	Vector Science and Therapeutics Corp. publie ses résultats pour le troisième trimestre et les neuf mois clos le 31 mai 2026	CI

Autres langues

28/07	Vector Science & Therapeutics Corp., LyoGenesis Plus 1, LLC And Wynn Pharmaceuticals LLC Announce Strategic Collaboration To Develop And Manufacture Critical Care Medical Products
27/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
25/07	Vector Science & Therapeutics Reports First Quarterly Financial Results as a Public Company; Announces Inaugural Investor Q&A on July 28
24/07	Vector Science and Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended May 31, 2026
21/07	Vector Science to Build Distributor Network For Peptide Portfolio Commercialization
21/07	Vector Science & Therapeutics Announces Distributor Network Buildout to Support Its Peptide Portfolio Across Orthopedic, Sports, and Regenerative Medicine Channels
17/07	Vector Science & Therapeutics Corp. and Caresyntax Enters Strategic Partnership for Real-World Evidence Program for Vectormist
17/07	Vector Science & Therapeutics Partners with Surgical Intelligence Company Caresyntax
17/07	Vector Science & Therapeutics and Caresyntax Announce Real-World Evidence Partnership for VectorMist
15/07	Vector Science & Therapeutics Expands Intellectual Property Portfolio with 15 Patent Applications Around Precision Therapeutic Delivery
15/07	Vector Science & Therapeutics Builds 15-Patent-Application Intellectual Property Portfolio Around Precision Therapeutic Delivery, Anchored by Peptide and Biologic Administration Technologies
08/07	Vector Science and Therapeutics Corp. Appoints Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board
07/07	Vector Science & Therapeutics Corp. Enters Exclusive Licensing and Manufacturing Agreement With LyoGenesis Plus
07/07	Vector Science & Therapeutics Announces Landmark Exclusive cGMP Manufacturing Agreement with LyoGenesis Plus for Its Proprietary Peptide Portfolio
30/06	Vector Science & Therapeutics Files Provisional Patent for Wearable Transdermal Peptide Delivery Platform
30/06	Vector Science & Therapeutics Files Provisional Patent for Breakthrough Transdermal Peptide Delivery Platform
22/06	Gary Payton II Named Chief Athletic Ambassador of Valor
15/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
12/06	Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform
12/06	Vector Science & Therapeutics Corp. Announces Appointment of Dexter Fowler as Chief Athletic Officer for Its Valor Platform
08/06	Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor
08/06	Vector Science & Therapeutics Corp. Announces Appointment of Darryl Drake Jr. as President of Valor and Chairman of the Athletic Board of Directors
02/06	Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy
13/05	Vector Science and Therapeutics enters option to buy up to 15% of Lyogenesis Plus for up to $1 million
13/05	Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing